
US is planning $500m project on 'universal vaccines;' WSJ
The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.
Newsletters and Deep Dive digital magazine
The US will spend $500m to develop universal vaccines against multiple virus variants, while planned changes to testing rules are raising concerns.
An AI-powered tool for triaging patients with suspicious skin lesions, developed by Skin Analytics, will be used by the NHS to reduce waiting times.
Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).
GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.
AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.
Editor's Picks
Newsletters and Deep Dive
digital magazine